Elena Élez

Abstract LB413: Peripheral blood as the sole source for cancer neoantigen and reactive T cell discovery

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i> -Mutated Colorectal Cancer

EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases

Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.

ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i>^V600E-Mutant Metastatic Colorectal Cancer

Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF<i>V600E</i>-Mutant<i>KRAS</i>Wild-Type Metastatic Colorectal Cancer

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.

Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers